Leading the Way in Life Science Technologies

GEN Exclusives

More »

GEN News Highlights

More »
Mar 13, 2008

BAC and Octapharma to Develop Custom Ligand for Recombinant Plasma Protein

  • BAC entered into a collaboration with Octapharma, a plasma protein company specializing in the development, production, and sale of plasma derivatives and recombinant plasma proteins. The objective of the collaboration is to discover and develop a custom CaptureSelect® ligand for the purification of a recombinant Factor IX product developed by Octapharma for the prophylaxis and treatment of bleeding in Haemophilia B.

    Octapharma will use the CaptureSelect ligand in the downstream processing of this protein from mammalian cell lines.



Be sure to take the GEN Poll

Cancer vs. Zika: What Worries You Most?

While Zika continues to garner a lot of news coverage, a Mayo Clinic survey reveals that Americans believe the country’s most significant healthcare challenge is cancer. Compared to other diseases, does the possibility of developing cancer worry you the most?

More »